1 Abbreviated Title: Neoadjuvant IO for HNSCC Version Date: August 31, 2022 Abbreviated Title: Neoadjuvant IO for HNSCC NIH Protocol #: 20C0024 Version Date: August 31, 2022 NCT Number: NCT04247282 Title: A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-β trap (M7824) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection. NCI Principal Investigator: Jason M. Redman, MD Genitourinary Malignancies Branch (GMB) Center for Cancer Research (CCR) National Cancer Institute (NCI) Building 10, Rm 13N240 10 Center Drive Bethesda, MD 20892 Phone: 240-858-3305 E-mail: jason.redman@nih.gov ETBX-011 ETBX-061 ETBX-051 Drug Name M7824 (Bintrafusp alfa, MSB0011359C) N-803 (ALT-803) Collectively called TriAd vaccine Sponsor CCR, NCI IND Number 019285 Manufacturer EMD Serono ImmunityBio, Inc. (previously NantCell)ImmunityBio, Inc.